LitCovid-sample-sentences  

PMC:7441788 / 39125-42371 JSONTXT 21 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T265 0-2 Sentence denotes 7.
T266 4-14 Sentence denotes Discussion
T267 15-73 Sentence denotes At present, the COVID-19 pandemic is continuing worldwide.
T268 74-171 Sentence denotes It is still an urgent need to find effective therapies and vaccines for treatment and prevention.
T269 172-298 Sentence denotes CQ/HCQ have diverse biological activities, and their mechanisms against CoVs including SARS-CoV-2 are not yet fully clarified.
T270 299-478 Sentence denotes Current studies show that CQ/HCQ can prevent receptor recognition by CoVs, inhibit endosome acidification, which interferes membrane fusion, and exhibit immunomodulatory activity.
T271 479-565 Sentence denotes These multiple mechanisms may work together to exert a therapeutic effect on COVID-19.
T272 566-727 Sentence denotes A number of in vitro studies have revealed that CQ/HCQ have inhibitory effects on various CoVs, including SARS-CoV [12,13], MERS-CoV [10] and SARS-CoV-2 [16–18].
T273 728-830 Sentence denotes However, conflicting results also exist on the in vitro activity of CQ/HCQ against SARS-CoV-2 [17,18].
T274 831-1045 Sentence denotes Several clinical studies have shown that CQ/HCQ may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay the progression of the disease, with less serious adverse effects [48,50,57,58,].
T275 1046-1190 Sentence denotes However, previous studies showed that CQ had anti-Ebola virus activity in cell culture, but it had conflicting results in animal models [71,72].
T276 1191-1355 Sentence denotes In addition, CQ has shown beneficial results against chikungunya virus in vitro, but in animal models it aggravates the infection and lacks therapeutic effect [73].
T277 1356-1601 Sentence denotes More importantly, in recent studies the use of HCQ did not show any favorable effect on patients with COVID-19 and high-dose CQ treatment of severe COVID-19 patients may even increase the risks of mortality and QTc interval prolongation [49,55].
T278 1602-1689 Sentence denotes In addition, the optimal daily dose and duration of treatment course are not yet clear.
T279 1690-1851 Sentence denotes One study suggested that the dose of HCQ should be 400 mg/2 times for 1 day, 200 mg/2 times/day for 4 days based on the physiological pharmacokinetic model [18].
T280 1852-2188 Sentence denotes A prospective study of HCQ on COVID-19 patients (13 cases) admitted to the ICU in France showed that the first daily dose of 800 mg/1 time for 1 day, and 200 mg/2 times/day for 7 days was recommended to maintain the HCQ treatment level (1–2 mg/l) based on physiologically pharmacokinetic (PBPK) models for COVID-19 patients in ICU [67].
T281 2189-2281 Sentence denotes Whether the dosage of CQ or HCQ should be varied according disease severity is also unclear.
T282 2282-2397 Sentence denotes A rodent study showed that CQ could exert anti-HCoV-OC43 activity transplacentally or by way of maternal milk [14].
T283 2398-2553 Sentence denotes However, in humans, the efficacy of CQ in the prevention and treatment of SARS-CoV-2 infection to both the mother and the child remains to be investigated.
T284 2554-2731 Sentence denotes Clinical trials in France showed that HCQ combined with azithromycin could enhance the virus clearance [50], but the subsequent reports did not support this combination [59,61].
T285 2732-2902 Sentence denotes Furthermore, CQ/HCQ alone or in combination with a macrolide induced high rate of adverse effects, especially prolonged QTc, in the use for COVID-19 treatment [61,68,69].
T286 2903-3246 Sentence denotes Therefore, current data are not sufficient enough to support the routine use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken for the application of CQ/HCQ, alone or in combination with other drugs, in COVID-19 before the conclusive findings are obtained by well-designed, multicenter, randomized, controlled studies.